Interim RAPID-PE Study Reveals ‘Excellent’ Safety Data in First 50 Patients

Interim RAPID-PE study reveals ‘excellent’ safety data in first 50 patients

Bashir endovascular catheter Prespecified interim analysis data from the first 50 patients in RAPID-PE have demonstrated “excellent safety” and “remarkably efficient lab times” in patients receiving on-the-table pharmacomechanical lysis without any post-procedure infusion with the Bashir endovascular catheter (Thrombolex) for the treatment of intermediate-risk acute pulmonary embolism (PE). The findings were presented during the 2025 Transcathet…

Thrombolex Bashir Catheter for Acute PE Studied in Interim Analysis of RAPID-PE

October 28, 2025—Thrombolex, Inc. announced findings from a prespecified interim analysis from the first 50 patients in the postmarket RAPID-PE study. The prospective, multicenter, single-arm United States RAPID-PE study is evaluating the safety and efficacy of on-the-table (OTT) pharmacomechanical lysis (PML) without postprocedure infusion using the company’s Bashir endovascular catheter (BEC) for the treatment of intermediate-risk acute pulmon…